5-amino-5,6,7,8-tetrahydroquinolin-2(1H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-amino-5,6,7,8-tetrahydroquinolin-2(1H)-one
• 英文别名: 5-amino-5,6,7,8-tetrahydro-1H-quinolin-2-one
• 化学式: C₉H₁₂N₂O
• mdl: MFCD01076938
• 分子量: 164.2
• InChiKey: CEXVAVXEVFFVEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Dimeric compounds
  申请人：——

  公开号：US20020156096A1

  公开（公告）日：2002-10-24

  The invention relates to dimeric compounds comprising two 5-amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group, processes for their preparation, intermediates for their preparation, pharmaceutical compositions containing such dimeric compounds and the use of such compounds as cholinesterase inhibitors and in the treatment of neurodegenerative diseases, such as Alzheimer's Disease and myasthenia gravis.

  这项发明涉及由双价连接基团连接在一起的两个5-氨基-5,6,7,8-四氢喹啉片段构成的二聚化合物，以及其制备方法、制备中间体、含有这种二聚化合物的药物组合物，以及将这种化合物用作胆碱酯酶抑制剂和治疗神经退行性疾病，如阿尔茨海默病和重症肌无力的用途。
• Diagnosis and treatment system for "reward deficiency syndrome" (RDS) and related behaviors
  申请人：Blum Kenneth

  公开号：US20060079495A1

  公开（公告）日：2006-04-13

  The present invention relates to a kit and an intravenously administrable preparation, both with a signal transmitter precursor, an enhancer of precursor uptake, and an inhibitor of neurotransmitter reuptake or signal transmitter catabolism. The kit also contains an appropriate swab for obtaining oral cells suitable for allelic analysis. The intravenous formulation contains similar materials and, in some cases, ethanol. Either the kit composition or the intravenous formulation may be used as guided by a subjects allelic analysis. Collections of particular alleles, especially those relating to neural system are comprehensible in terms of likelihood of success in the administration of an intraveinous formulation or ingestion of components of the subject kit.

  本发明涉及一种试剂盒和一种可静脉注射的制剂，两者都含有一种信号传递前体、一种前体摄取增强剂和一种神经递质再摄取或信号传递分解抑制剂。试剂盒中还含有适当的拭子，用于获取适合进行等位基因分析的口腔细胞。静脉注射制剂含有类似的材料，在某些情况下还含有乙醇。试剂盒成分或静脉注射制剂均可用于受试者等位基因分析。特定等位基因的集合，特别是那些与神经系统有关的等位基因，可以从静脉注射制剂或摄入受试者试剂盒成分的成功可能性方面进行理解。
• ALLELIC POLYGENE DIAGNOSIS OF REWARD DEFICIENCY SYNDROME AND TREATMENT
  申请人：Kenneth Blum, Inc.

  公开号：EP0979092A2

  公开（公告）日：2000-02-16
• US6132724A
  申请人：——

  公开号：US6132724A

  公开（公告）日：2000-10-17
• US6472408B1
  申请人：——

  公开号：US6472408B1

  公开（公告）日：2002-10-29